Pembrolizumab Combined With GDP Regimen Inducing Sustained Remission in Histiocytic Sarcoma: A Case Report
Histiocytic sarcoma (HS) is a rare hematopoietic neoplasm with an aggressive clinical course and a poor response to conventional chemotherapy. Currently, no standard treatment paradigms are available. Herein, we present a case of de novo HS treated with pembrolizumab combined with a GDP regimen (gem...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publishing
2024-08-01
|
| Serie: | Journal of Investigative Medicine High Impact Case Reports |
| Accesso online: | https://doi.org/10.1177/23247096241274561 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|